View in EDS HTML Full Text PDF Full Text

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Saved in:
Bibliographic Details
Title: Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
Authors: Castro, Januario E.1,2 (AUTHOR), Lengerke-Diaz, Paula A.1 (AUTHOR), Velez Lujan, Juliana2 (AUTHOR), Choi, Michael Y.2,3 (AUTHOR), Moreno-Cortes, Eider F.1 (AUTHOR), Forero, Jose V.1 (AUTHOR), Garcia-Robledo, Juan Esteban1 (AUTHOR), Jacobs, Chaja3 (AUTHOR), McCarthy, Colin3 (AUTHOR), Heinen, Alaina3 (AUTHOR), Amaya-Chanaga, Carlos I.4 (AUTHOR), Kipps, Thomas J.2,3 (AUTHOR)
Source: Advances in Hematology. 1/22/2022, p1-8. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:16879104
DOI:10.1155/2022/4450824